Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 12680 in total
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Description: … Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination ... insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. ... Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes …
Matched Categories: … combinations of sulfonamides …
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of
Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.
Approved
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA...
Approved
Vet approved
Matched Description: … [A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting …
Matched Categories: … combinations of sulfonamides …
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Approved
Investigational
Matched Description: … molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of
Matched Categories: … Sex Hormones and Modulators of the Genital System …
Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis. Gestrinone was developed in the early 1970s and was tested clinically as...
Approved
Matched Description: … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group ... , and Latin America, though not the United States or Canada, and is used primarily in the treatment of
Matched Categories: … Sex Hormones and Modulators of the Genital System …
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn
Matched Description: … In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. ... Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension …
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Approved
Matched Description: … Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. …
A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Approved
Investigational
Matched Description: … blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together...
Approved
Investigational
Matched Description: … Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet ... Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical …
Matched Categories: … Preparations for Treatment of Wounds and Ulcers …
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved
Matched Description: … It is used in the management of severe pain. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Description: … [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003 ... [A258313] The use of vardenafil as a monotherapy for the treatment of pulmonary arterial hypertension ... cGMP in the smooth muscle cells of the corpus cavernosum. …
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Matched Description: … TCAs are potent inhibitors of serotonin and norepinephrine reuptake. ... See toxicity section below for a complete listing of side effects. ... Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative …
Matched Categories: … Combined Inhibitors of Serotonin/Norepinephrine Reuptake ... Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.
Approved
Matched Description: … Minaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive ... Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of...
Approved
Matched Description: … of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency ... 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of ... for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. …
Matched Categories: … Ethers of Tropine or Tropine Derivatives …
An antipsychotic agent used in schizophrenia. [PubChem]
Approved
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties.[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for its possible...
Approved
Investigational
Matched Description: … Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of ... treatment for COVID-19-induced pulmonary complications due to its ability to regulate the production of ... [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced …
Matched Categories: … combinations of xanthines …
Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was...
Approved
Illicit
Matched Description: … Opium is the first substance of the diverse group of the opiates. ... harmful effects of opium. ... in the category of isoquinolines. …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Approved
Matched Categories: … Combined Inhibitors of Serotonin/Norepinephrine Reuptake ... Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Displaying drugs 751 - 775 of 12680 in total